Medicinal Products

Dáil Éireann Debate, Tuesday - 16 June 2026

• Díospóireachtaí
• Aimsigh díospóireacht
  • Díospóireachtaí na Dála
  • Díospóireachtaí an tSeanaid
  • Díospóireachtaí Coiste
• Aimsigh vótáil
  • Vótálacha na Dála
  • Vótálacha an tSeanaid
  • Vótálacha Coiste
• Ceisteanna Parlaiminte
  • Ceisteanna scríofa
  • Ceisteanna ó bhéal
• Leideanna cuardaigh
• Nuair a bhíonn tionchar tromchúiseach ag aithrisí

Tuesday, 16 June 2026

Ceisteanna (940)

Michael Collins

Ceist:

940. Deputy Michael Collins asked the Minister for Health the reason the HSE has not yet approved funding for the drug dupixent (dupilumab) for adults with eosinophilic oesophagitis; the stage the pricing and assessment process is currently at; when a decision is expected; and if she will make a statement on the matter. [45320/26]

Freagraí scríofa

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• An Freagra Roimhe Sin
• An Chéad Fhreagra eile